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Abstract 13 
AP-1 is a clathrin adaptor recruited to the trans-Golgi Network where it can interact with 14 
specific signals found in the cytosolic tail of cargo proteins to incorporate them into clathrin-15 
coated vesicles for trafficking. The small G protein Arf1 regulates the spatiotemporal 16 
recruitment of AP-1 and also drives a conformational change favoring an interaction with cargo 17 
proteins. A recent crystal structure and in vitro experiments highlighted potential residues 18 
mediating the AP-1/Arf1 interaction and the unlocking of the complex. We have used 19 
bioluminescence resonance energy transfer (BRET) to study the Arf1/AP-1 interaction and AP-1 20 
conformational changes in vivo. We identified novel residues required for this interaction in 21 
addition to those predicted in the crystal structure. We also studied the conformational changes 22 
in AP-1 driven by Arf1 in live cells and found that opening of the complex is prerequisite for 23 
oligomerization. Using Arf1 knockout cells generated by CRISPR/Cas9, we demonstrated that 24 
residue 172 in Arf1 is necessary for AP-1 activation and is required for the efficient sorting of the 25 
lysosomal protein prosaposin. We have used BRET to study the in vivo activation of AP-1. The 26 
advantages of BRET include expressing full-length proteins in their native environment that have 27 
been fully post-translationally modified. 28 
 29 
Introduction 30 
The formation of clathrin-coated vesicles (CCVs) plays an important role in the 31 
intracellular transport of integral membrane and intraluminal proteins from one membrane 32 
compartment of the cell to another. Adaptor protein complexes perform dual roles in binding 33 
specific peptide motifs on membrane-associated cargo proteins and recruit clathrin to drive 34 
vesicle formation 1. 35 
The adaptor protein complex 1 (AP-1) is a heterotetrameric complex composed of two 36 
large subunits (β1 and γ), a medium subunit (µ1) and a small subunit (σ1) involved in traffic 37 
between the trans-Golgi network (TGN) and endosomes 2,3. Structurally, AP-1 consists of a 38 
“core” domain made of the N-terminal portions of the β1 and γ subunits plus the entire µ1 and 39 
σ1 subunits. Outside of the core domain, the C-terminal part of β1 and γ form two “appendage” 40 
domains involved in the interaction with clathrin and other accessory proteins 3. The core 41 
domain recruits the complex to membranes and recognizes sorting sequences in the cytosolic 42 
tail of cargo proteins such as tyrosine (YXXØ, where X is any amino acids and Ø is a bulky 43 
hydrophobic amino acid) or dileucine ([D/E]XXXL[L/I])-type signals 4-6. Besides interaction with 44 
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cargo proteins, binding of the γ subunit to phosphatidylinositol-4-phosphate (PI(4)P) also 45 
facilitates AP-1 recruitment to membranes 7. However, the main factor targeting AP-1 to the 46 
membrane of endosomes and the TGN are members of the ADP ribosylation factor (Arf) family 47 
of small GTPases. Arf1, for example, recruits AP-1 to TGN membranes, followed by the binding 48 
of clathrin to the adaptors and the formation of CCVs 8,9. Whereas the GDP bound form of Arf1 is 49 
cytosolic, the exchange of GDP for GTP leads to conformational changes in Arf1 exposing a 50 
myristoyl group and an associated N-terminal amphipathic helix, critical for Arf1 membrane 51 
binding 10,11. These conformational changes extend to the switch I-II domains of Arf1, allowing it 52 
to interact with various effectors such as AP-1. 53 
The crystal structure of the AP-1 core domain with a GTP-bound N-terminal truncated 54 
form of Arf1, revealed two interaction interfaces between the switch I-II domains of Arf1 and 55 
the β1 and γ subunits 12. In vitro binding experiments suggest that these interfaces are necessary 56 
for high affinity binding of AP-1 to Arf1 12. Another striking feature of this crystal structure seems 57 
to suggest that Arf1 drives a conformational change in the AP-1 complex from a “locked” to an 58 
“open” conformation able to interact with tyrosine or dileucine-based signals of cargo proteins 59 
12,13. Based on in vitro experiments, a third interaction interface between the C-terminal back-60 
side of Arf1 and the γ subunit of AP-1, would not be necessary for the interaction between these 61 
two proteins, but would participate in the allosteric activation of AP-1 12. So far, much of what is 62 
known regarding AP-1 recruitment and activation is based on in vitro experiments using 63 
truncated forms of the proteins. However, the next step toward a more complete understanding 64 
of these mechanisms will require the study of full-length forms of AP-1 and Arf1 in their natural 65 
cellular environment. 66 
In recent years, resonance energy transfer (RET)-based techniques like fluorescence 67 
resonance energy transfer (FRET) and bioluminescence resonance energy transfer (BRET) have 68 
increasingly been used to study protein-protein interaction 14,15, intra or inter-molecular 69 
conformational changes 16-19 and ligand-binding 20 in living cells, in real time and with proteins 70 
expressed in their natural environment. RET is a phenomenon occurring when the emission 71 
spectrum of a donor chromophore overlaps with the excitation spectrum of an acceptor 72 
chromophore allowing for the non-radiative transfer of energy from the donor, following its 73 
excitation, to the acceptor molecule. The RET efficacy is inversely proportional to the sixth 74 
power of the distance between the donor and acceptor and will not occur if the two 75 
chromophores are separated by more than   ̴10 nm 21. As such, the occurrence of RET between 76 
chromophores attached to two proteins can be interpreted as a direct interaction between 77 
these proteins or their presence in a multi-protein complex. In BRET, the donor chromophore is 78 
the bioluminescent enzyme Renilla luciferase (RlucII), whereas in FRET it is a photoexcitable 79 
chromophore. Since RlucII is excited by the addition of an enzyme substrate instead of an 80 
external light beam, as is the case for FRET, the main advantage of BRET over FRET is the 81 
absence of background emission coming from non-specific cell excitation. 82 
Therefore, we sought to study the interaction between Arf1 and AP-1 and the 83 
conformational changes in the AP-1 complex in living cells using BRET2 technology. We found 84 
that BRET2 can detect the interaction between Arf1 and AP-1 and the decreased affinity caused 85 
by mutations in Arf1 or AP-1 subunits. BRET2 was also successfully used to detect the 86 
conformational changes associated with the activation of AP-1 and the role Arf1 plays in the 87 
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unlocking of the complex. Finally, we found that Arf1 increases AP-1 oligomerization by 88 
recruiting it to membranes and changing its conformation. 89 
 90 
Results 91 
Detection of the Arf1/AP-1 interaction using BRET 92 
 In order to detect the formation of a complex between Arf1 and AP-1 in living cells, Arf1 93 
was fused at its C-terminus to the energy donor Renilla luciferase II (Arf1-RlucII) and the β1 and 94 
γ subunits of AP-1 were fused at their C-terminus to the blue-shifted green fluorescent protein 95 
10 (β1-GFP10 or γ-GFP10) energy acceptor. Although GFP-tagged version of Arf1 22,23 and β1 12 96 
have been described before, we first sought to determine if the presence of a larger tag like 97 
RlucII or GFP10 could affect the function of either Arf1 or β1. As seen in Figure 1A, a membrane 98 
isolation assay performed in HEK293T cells transfected with Arf1-RlucII confirms that Arf1 99 
retains its ability to bind membranes when fused to RlucII. Moreover, a GTP-locked mutant of 100 
Arf1 (Arf1Q71L-RlucII) displays increased membrane association (Figure 1A), suggesting that the 101 
presence of RlucII at the C-terminus of Arf1 does not interfere with its activation. Nevertheless, 102 
it was previously shown that the presence of a c-terminal tag on Arf1 (GFP or HA) can affect its 103 
GTP exchange and hydrolysis 24 and we cannot exclude the possibility that the presence of the 104 
RlucII tag might influence Arf1 function. We then sought to determine if the presence of GFP10 105 
at the C-terminus of β1 could interfere with its ability to interact with other AP-1 subunits. For 106 
this purpose, β1-GFP10 was transfected in HEK293T cells and immunoprecipitated using an 107 
antibody against GFP. Western blot analysis using an antibody against the γ subunit revealed 108 
that β1-GFP10 interacts with endogenously expressed γ (Figure 1B), suggesting that it is 109 
integrated into AP-1 complexes. 110 
We next detected the association between Arf1 and AP-1 in living cells by generating 111 
BRET titration curves in which a fixed amount of the donor Arf1-RlucII (WT or mutant) was co-112 
transfected in HEK293T cells with increasing quantities of the acceptor β1-GFP10. As seen in 113 
Figure 2A (black line), the accumulation of β1-GFP10 gradually increases the BRET signal with 114 
wild-type Arf1-RlucII ultimately reaching a plateau, suggesting that the BRET signal is coming 115 
from a specific interaction and not random collision 25. The highly conserved threonine 48 116 
residue of Arf1, involved in the GDP to GTP exchange 26, was mutated to serine to decrease the 117 
activation of Arf1. This mutation did not alter the expression level of Arf1 compared to wild-type 118 
(Figure S1), but it lead to a decrease of BRET with β1-GFP10 and a linearization of the titration 119 
curve (Figure 2A, blue line). As seen in Figure 2A (red line), the constitutively active Arf1Q71L-120 
RlucII displays higher BRET signal with β1-GFP10 and the BRET50, the GFP10/RlucII ratio giving 50 121 
% of the BRETmax signal, is significantly lower than ARF1WT, suggesting a higher propensity to 122 
interact with AP-1 which is consistent with in vitro observations (Figure 2B). Simultaneously 123 
mutating T48S and Q71L (Arf1T48S,Q71L-RlucII) brought the BRETmax (Figure 2A) and BRET50 (Figure 124 
2B) to similar levels as for wild-type Arf1. The relatively low BRET signals observed between Arf1 125 
and AP-1 are probably explained by the distance between the RlucII and GFP10 tags as Arf1 sits 126 
very close to the membrane whereas the C-terminal extension of β1 is thought to be floating in 127 
the cytosol away from the membrane. We generated BRET titration curves with full length β1 128 
and β11-584 with Arf1Q71L-RlucII (Figure 2C). Indeed, removing the cytosolic ear of β1 and placing 129 
the GFP10 tag just outside the trunk of AP-1 (β11-584) significantly increased the BRETmax (Figure 130 
2D) with Arf1Q71L whereas the BRET50 (Figure 2E) was unaffected, suggesting that the C-terminal 131 
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extension of β1 does not influence the interaction with Arf1. Truncation of β1 did not affect its 132 
expression compared to wild-type β1 (Figure S2A). It has been suggested that the hyperbolic 133 
form of a BRET titration curve is not sufficient to conclude that the BRET signal is coming from a 134 
specific interaction 27,28. An alternative approach is to perform the BRET titration curves at 135 
different levels of donor expression and express the BRET ratio as a function of acceptor 136 
expression. In the case of non-specific interaction, the BRET ratio should be independent of 137 
donor levels, whereas for a specific interaction the BRET ratio should decrease with increasing 138 
levels of donor expression at similar levels of acceptor fluorescence 28. As seen in Figure S3, the 139 
BRET ratios between Arf1WT-RlucII (Figure S3A) or Arf1Q71L-RlucII (Figure S3B) and β1-GFP10 140 
decrease with increasing donor concentration confirming that the BRET signal observed 141 
between Arf1 and β1 is coming from a specific interaction. 142 
 143 
Reduced interaction between Arf1 and AP-1 mutants is detected by BRET in vivo 144 
 The crystallization of a truncated form of AP-1 with a truncated form of Arf1 lacking its 145 
N-terminus conjugated to GTP revealed a potential interaction interface between the β1 subunit 146 
of AP-1 and the switch 1 and 2 regions of Arf1. Mutation of some residues in that interface led 147 
to reduced binding in vitro 12. We first wanted to confirm the importance of these residues for 148 
the interaction between full-length AP-1 and Arf1 in vivo using BRET.  Arf1Q71L-RlucII was 149 
transfected into HEK293T cells with increasing concentrations of wild-type β1-GFP10 or 150 
β1I85,V88D-GFP10, at similar levels of expression (Figure S2B), to perform BRET titration 151 
experiments. As shown in Figure 3, the BRET titration curve for the mutated form of β1 (Figure 152 
3A, blue line) is shifted to the right leading to a higher BRET50 (Figure 3B) confirming the 153 
importance of these residues for the interaction between Arf1 and AP-1 in vivo. In contrast, the 154 
mutation of glutamine 59 (β1Q59E-GFP10, another β1 residue suggested by the crystal structure 155 
to make contact with Arf1, had no effect on the BRET50 (Figure 3B) indicating that mutating this 156 
residue alone is not sufficient to lead to a significant loss of binding. To ensure that the changes 157 
in the interaction of β1I85,V88D-GFP10 with Arf1 we observed in BRET were not a result of the 158 
mutant β1 not binding the other subunits of the complex and therefore not being incorporated 159 
into the complex, we performed a co-immunoprecipitation experiment (Figure 3C). Wild-type β1 160 
and the two mutants were able to interact with endogenous γ, suggesting that the three β1 161 
proteins were integrated into AP-1 complexes. BRET titration experiments between β1-GFP10 162 
and wild-type or mutated forms of Arf1-RlucII were next performed to test the role of the switch 163 
1 domain of Arf1 in the interaction with AP-1 in vivo (Figure 4A). As seen in Figure 4B, Arf1I49D,Q71L 164 
shows reduced interaction with β1-GFP10 (larger BRET50 value) compared to Arf1Q71L, confirming 165 
results previously obtained in vitro. However, mutation of valine 53 (Arf1V53E,Q71L), which 166 
significantly decreased the interaction in vitro, had no effect on the BRET between Arf1 and β1 167 
suggesting that this residue does not strongly contribute to the association in vivo (Figure 4B). 168 
Two novel mutations in the switch 1 region of Arf1 (F51D and N52D) also led to a rightward shift 169 
of the BRET titration curve (Figure 4A, red and purple lines) and a corresponding increase in 170 
their BRET50 (Figure 4B) confirming the role of this domain in the AP-1/Arf1 association. Similar 171 
experiments were also done with mutations in the switch 2 region of Arf1 (Figure 4C). 172 
Interestingly, Arf1Q71L,L77D,H80D, a mutant shown to lose all interaction with AP-1 in vitro, displayed 173 
similar BRET50 to Arf1Q71L in vivo, suggesting a minimal role of these residues in the AP-1/Arf1 174 
interaction in vivo (Figure 4D). However, two novel mutations (Y74D and Y81D) showed a 175 
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significant increase in BRET50 compare to wild-type (Figure 4D), confirming that the switch 2 176 
domain is also involved in the recruitment of AP-1 to Arf1. All Arf1 mutants used in this study 177 
maintained co-localization with the Golgi marker giantin (Figure S4 and S5) suggesting that any 178 
loss in interaction was not due to mis-localization of Arf1. 179 
Though not visible in the crystal structure, a second binding interface between the 180 
switch 1/2 region and the N-terminus of the γ subunit has also been proposed to be involved in 181 
AP-1 recruitment to Arf1 12. We sought to determine if residues in γ essential for the binding to 182 
Arf1 in vitro, are also important in vivo by performing BRET titration experiments. Wild-type γ 183 
efficiently binds to Arf1 as shown by the saturated curve (Figure 5A, black line). The two γ 184 
mutants (γL68D,L71D and γL102D) display a significant decrease in BRET signal compare to wild-type γ, 185 
at similar levels of expression (Figure S2C), suggesting that this interface also plays a role in the 186 
AP-1/Arf1 association in vivo (Figure 5A). The absence of saturation for γL68D,L71D and γL102D (Figure 187 
5A, blue and red points) suggest these γ mutants have completely lost their ability to interact 188 
with Arf1 in cells. The change in the interaction with Arf1 was not due to the mutant γ subunits 189 
not integrating into the AP-1 complex as wild-type and mutant γ were able to co-190 
immunoprecipitate with β1-RlucII (Figure 5B). 191 
 192 
Monitoring AP-1 conformational changes by BRET 193 
 The crystal structure of AP-1 with Arf1-GTP revealed another binding interface between 194 
the back-side of Arf1 and the γ subunit of AP-1. Based on in vitro experiments, this interface 195 
would not be necessary for AP-1 recruitment to Arf1, but would participate in the activation of 196 
AP-1 by unlocking its conformation and allowing the C-terminal domain of µ1 to interact with 197 
membrane cargo 12. We first tested the role of this interface in vivo by generating BRET titration 198 
curves between wild-type Arf1-RlucII or various Arf1 mutants and β1-GFP10 (Figure 6A). 199 
Mutations in this region of Arf1 (W172D or A136, 137H) resulted in no significant changes in 200 
BRET50 suggesting that this interface is not involved in AP-1 binding to Arf1 (Figure 6B). An 201 
increase in BRETmax observed with Arf1Q71L,A136,137H-RlucII suggests that these mutations alter the 202 
conformation of Arf1 but not its ability to bind AP-1 (Figure 6A, red line). 203 
We next sought to monitor AP-1 conformational changes by tagging the γ subunit to 204 
RlucII (γ-RlucII) and the µ1 subunit to GFP10 (µ1-GFP10) and co-transfecting them into HEK293T 205 
cells. First, cells were treated with Brefeldin A (BFA), an Arf1 GEF inhibitor that leads to the 206 
inactivation of AP-1 29 or vehicle for the indicated times and the BRET between γ-RlucII and µ1-207 
GFP10 was measured. BFA treatment leads to an increase in BRET between the two AP-1 208 
subunits (Figure 7A) suggesting that the C-terminus of γ and µ1 are closer and in the “locked” 209 
conformation. It has been shown that AP-1 can oligomerize 30 and to decrease the possibility 210 
that the BRET increase observed reflects a change in the oligomerization status of AP-1 rather 211 
than a change in conformation, these experiments were performed at BRETmax where moderate 212 
changes in the oligomerization of AP-1 should have minimal effects on the BRET between γ-213 
RlucII and µ1-GFP10.  Moreover, BFA treatment should lead to a dissociation of AP-1 from the 214 
membrane and a decrease in the oligomerization of AP-1 that could not explain the increase in 215 
BRET between γ-RlucII and µ1-GFP10. Nevertheless, we also performed the BFA treatment 216 
experiment on cells transfected with β1-RlucII and β1-GFP10 where the BRET signal can only 217 
come from different AP-1 complexes.  When performing the assay at BRETmax, we saw no 218 
changes in BRET (Figure 7A) between β1-RlucII and β1-GFP10, confirming that the increase in 219 
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BRET between γ and µ1 comes from a conformational change of the complex and not from 220 
oligomerization. If this is true, increasing the proportion of active AP-1 in cells should lead to a 221 
decrease in BRET between γ-RlucII and µ1-GFP10. In order to test this, the two AP-1 subunits 222 
were co-transfected with a constitutively active form of Arf1 (Arf1Q71L-HA) or a mutant form 223 
(Arf1Q71L,W172D-HA) that was shown in vitro not to open the complex (Figure 7B). As expected, 224 
expressing Arf1Q71L-HA resulted in a decrease in BRET between γ-RlucII and µ1-GFP10 (Figure 225 
7C). Interestingly, overexpression of Arf1Q71L,W172D-HA only slightly decreased the BRET between 226 
γ-RlucII and µ1-GFP10 (Figure 7C) suggesting that even though this mutant binds normally to AP-227 
1 (Figure 6B), it is less efficient at driving AP-1 unlocking. We sought to confirm this result by 228 
performing rescue experiments in a CRISPR/Cas9 generated Arf1 knockout (Arf1-KO) cell line 229 
(Figure S6). The morphology, survival and growth rate of these cells is comparable to wild-type 230 
HEK293T cells. BRET titration curves between γ-RlucII and µ1-GFP10 were first performed in 231 
HEK293T or Arf1-KO cells (Figure 8A). As shown in Figure 8B, the BRETmax signal increased in 232 
Arf1-KO cells as expected as less AP-1 complex is activated whereas the BRET50 (Figure 8C) was 233 
unaffected indicating that the association between the two subunits is normal in the absence of 234 
Arf1. Mammalian Arfs possess high levels of similarities in their primary sequences and are often 235 
localized in the same compartment suggesting they might have redundant functions. This is 236 
supported by studies showing that simultaneous depletion of multiple Arfs is required to 237 
observe certain phenotypes 31-33. Our results suggest that Arf1 plays a specific role in the 238 
recruitment and activation of AP-1, though we cannot exclude that simultaneously knocking-out 239 
another Arf could lead to a more pronounced phenotype. We next performed rescue 240 
experiments by co-transfecting γ-RlucII and µ1-GFP10 with either Arf1WT-HA or Arf1W172D-HA in 241 
Arf1-KO cells. As shown in Figure 8D, wild-type Arf1 brought the BRETmax signal to a level similar 242 
to HEK293T cells whereas Arf1W172D only had a partial effect. This result confirms that even 243 
though Arf1W172D interacts with AP-1 with a similar affinity as wild-type Arf1, it is less efficient in 244 
driving the conformational change of the complex. In order to determine if the observed 245 
conformational change is associated with activation and normal function of AP-1, we co-246 
expressed Arf1-HA or Arf1W172D-HA with PSAP-myc in HEK293T or Arf1-KO cells and measured 247 
their ability to rescue the quantity of PSAP secreted outside the cells, a phenotype observed 248 
when disrupting normal trafficking pathways 34. The overexpression of wild-type Arf1 was able 249 
to decrease the secretion of PSAP in Arf1-KO cells, whereas Arf1W172D could not (Figure 8E). 250 
These results show that, in addition to recruiting AP-1 to the membrane, Arf1 stimulates a 251 
conformational change necessary for the function of AP-1 in vivo. 252 
 253 
Membrane recruitment and activation by Arf1 increases AP-1 oligomerization 254 
 Previous experiments with purified adaptor proteins and synthetic liposomes showed 255 
that Arf1 can induce AP-1 oligomerization 30 and models of AP-1 interaction with Arf1 suggest 256 
that AP-1 would need to bind Arf1 as a monomer first and then oligomerize at the membrane 12. 257 
We sought to determine the monomeric/oligomeric assembly of AP-1 in the cytosol and 258 
membrane compartments. The cytosol and membrane compartments of HEK293T cells 259 
transfected with β1-RlucII and β1-GFP10 were separated by cell fractionation and BRET was 260 
measured in each fraction. As shown in Figure 9A, the BRET signal coming from membrane 261 
compartments is significantly stronger than the BRET observed in the cytosol. The later may be 262 
explained by contamination of the cytosolic fraction with membranes or that a small proportion 263 
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of AP-1 could exist as oligomer in the cytosol. We next performed BRET titration experiments in 264 
HEK293T cells expressing β1-RlucII or β1-GFP10 with Arf1Q71L-HA, Arf1Q71L,W172D-HA or mock 265 
transfected, to determine if recruitment of AP-1 to the membrane by Arf1 leads to its 266 
oligomerization (Figure 9B and C). The BRET50 for the association between β1-RlucII and β1-267 
GFP10 decreased by almost 4 fold in the presence of Arf1Q71L (Figure 9D) suggesting that 268 
recruitment of AP-1 by Arf1 increases its oligomerization. Interestingly, Arf1Q71L,W172D is less 269 
efficient at driving AP-1 oligomerization (Figure 9D), even though it is as or even more potent in 270 
increasing AP-1 membrane association than Arf1Q71L (Figure 9E). Together, these results indicate 271 
that higher level of AP-1 oligomerization requires both the membrane association and 272 
conformational changes associated with its activation. 273 
 274 
Discussion 275 
The interaction of the multimeric adaptor protein (APs) complexes and COPI with Arf1, 276 
and their subsequent activation have been extensively studied in vitro 12,35,36. We took 277 
advantage of BRET to study the interaction between Arf1 and AP-1, and how this interaction 278 
leads to the activation of the complex in live cells using full-length proteins in their native 279 
environment.  280 
The crystal structure of Arf1 interacting with AP-1 revealed multiple interaction 281 
interfaces. The switch I/II regions of Arf1 mediates interaction interfaces with both β1 and γ 282 
subunits of AP-1. Based on structural data, at least 3 residues in β1 (Gln59, Ile85 and Asn89) 283 
should be important for binding Arf1 12. By overlaying β1 and γ, a model for Arf1 bound to γ was 284 
generated and identified potentially important residues (Leu68, Leu71 and Leu102). In vitro 285 
binding experiments using mutations in both β1 and γ prevented a stable interaction with Arf1. 286 
Our in vivo data using BRET supports this conclusion. We also tested β1Q59E, which was not 287 
reported in the in vitro experiments. We found no changes in the interaction between Arf1 and 288 
AP-1 suggesting a lesser contribution of this residue to the AP-1/Arf1 interaction in vivo.  289 
Based on the crystal structure, several residues in the switch I/II domains of Arf1 were 290 
predicted to be important for its interaction with AP-1. In vitro studies showed that Arf1 switch I 291 
residues Ile49 and Val53 and switch II residues Lys73, Leu77 and His80 are required for its 292 
interaction with AP-1. However, other switch I residues (Phe51 and Asn52) and switch II residues 293 
(Ile74 and Tyr81) were also predicted to mediate this interaction but their roles in the 294 
interaction were not reported. Our in vivo studies confirmed the role of Ile49 in binding AP-1. 295 
Interestingly, mutations at Val53, Leu77 and His80 did not affect binding between Arf1 and AP-1 296 
using BRET. Furthermore, when we tested Phe51, Asn52, Ile74 and Tyr81, all had significant 297 
effects on the interaction. Our in vivo experiments confirm the role of switch I/II in mediating 298 
the interaction between Arf1 and AP-1. However, the discrepancy observed between the in vitro 299 
and in vivo experiments highlights the possibility that the interface conformation observed in 300 
vitro is slightly different. This could be due to using truncated proteins (Arf1, β1 and/or γ), the 301 
lack of a membrane environment or the lack of post-translational modifications in the in vitro 302 
experiments. 303 
A third interface predicted by the crystal structure between the backside of Arf1 and γ 304 
was tested using various Arf1 mutations. It was predicted that Ala136, Ala137 and Trp172 of 305 
Arf1 were important in the binding to γ. In vitro, these mutations (Arf1A136,137H and Arf1W172D) did 306 
not prevent the interaction between Arf1 and AP-1, but surprisingly increased it. These residues 307 
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were suggested to be involved in the activation of the complex based on an in vitro assay where 308 
Arf1W172D is less efficient in promoting cargo protein binding to AP-1. In our in vivo studies, we 309 
found no significant changes in the affinity between these Arf1 mutants and AP-1, confirming 310 
that they were not necessary for binding. By tagging the γ and µ1 subunits to RlucII and GFP10 311 
respectively, we were able to directly detect the conformational changes associated with the 312 
unlocking of AP-1 in live cells and confirm the allosteric function of Trp172 in Arf1 in the 313 
activation of AP-1. Moreover, using an Arf1-KO cell line displaying aberrant secretion of the 314 
lysosomal protein prosaposin, we were able to correlate the unlocking of AP-1 to its function in 315 
lysosomal trafficking, as Arf1W172D was less efficient than Arf1WT in rescuing prosaposin secretion.    316 
Although the crystal structure of Arf1-GTP with AP-1 revealed a dimeric 2:2 Arf1: AP-1 317 
assembly, modeling suggests that the γ/switch I/II recruitment interface is incompatible with 318 
binding of a dimer of AP-1 12. Therefore, it was proposed that Arf1 first binds AP-1 in its closed 319 
state as a monomer and once on the membrane, AP-1 would dimerize. Consistent with this 320 
hypothesis, we found that AP-1 exists predominantly as a monomer in the cytosol whereas it 321 
forms dimers or oligomers when recruited to membranes. Furthermore, by overexpressing a 322 
constitutively active form of Arf1 (Arf1Q71L) we were able to increase the oligomerization of AP-1 323 
whereas the activation deficient mutated form of Arf1 (Arf1Q71L,W172D) resulted in less 324 
oligomerization. This suggests that higher order oligomerization of AP-1 requires the 325 
conformational changes associated with the activation of the complex. Interestingly, a recent 326 
report on the complex between AP-1, Arf1 and the HIV Nef protein suggest that Arf1W172D is less 327 
efficient in driving higher order oligomers of AP-1 based on size exclusion chromatography 35. 328 
In summary, we have used BRET to determine the interaction sites between Arf1 and 329 
AP-1, as well as to directly study the conformational changes in AP-1 driven by Arf1 in live cells. 330 
As far as we know, this is the first time that conformational changes in AP-1 have been directly 331 
monitored in live cells. This technique could be efficiently used to study other protein complexes 332 
in vivo including the association between small GTPases and their effectors. We propose that 333 
BRET is a useful tool to study protein complexes in live cells because full-length proteins are 334 
expressed in their native environments that are post-translationally modified. BRET has the 335 
additional benefit of being significantly less labor intensive than purifying proteins from 336 
bacterial lysates and can be performed in 96 or 384-well plates which makes its suitable for 337 
high-throughput screening.  338 
 339 
Materials and Methods 340 
 341 
Reagents and antibodies 342 
 All reagents, unless specified, were purchased from Fisher Scientific (Ottawa, ON). 343 
Dulbecco’s modified Eagle’s medium, fetal bovine serum and penicillin-streptomycin were 344 
purchased from Wisent (St-Bruno, Qc, Canada). Linear 25 kDa polyethyleneimine (PEI) was from 345 
Polysciences Inc. (Warrington, PA). Coelenterazine 400a and coelenterazine h were purchased 346 
from Prolume Ltd. (Pinetop, AZ). Brefeldin A was purchased from Molecular Probes (Eugene, 347 
OR). The protease inhibitor cocktail was purchased from Sigma-Aldrich (Oakville, ON). The 348 
following mouse monoclonal antibodies were used: anti-hemagglutinin (anti-HA) antibody 349 
(MMS-101P, Cedarlane Laboratories, Burlington, ON); anti-myc antibody (MMS-105P, Cedarlane 350 
Laboratories); anti-γ antibody (A4200, Sigma-Aldrich, Oakville, ON); anti-actin (612657, BD 351 
9 
Biosciences, Mississauga, ON); anti-Renilla luciferase (MAB4410) antibody (16932-1-AP) was 352 
purchased from EMD Millipore (Billerica, MA). The following rabbit polyclonal antibodies were 353 
used: anti-GFP antibody (ab290, Abcam, Cambridge, MA); anti-ARF1 antibody (20226-1-AP, 354 
Proteintech, Chicago, IL). Anti-mouse and anti-rabbit horseradish peroxidase-conjugated IgG 355 
were from GE Healthcare (Chalfont St.Giles, Buckinghamshire, UK). 356 
 357 
Eukaryotic expression vectors 358 
 Human Arf1 was amplified by PCR minus the methionine initiation site and subcloned in-359 
frame upstream of RlucII into the pcDNA 3.1 (+) vector to create the Arf1-RlucII construct. 360 
Human γ, β1 and µ1 were amplified by PCR minus the stop codon and subcloned in-frame 5’ of 361 
RlucII into the pcDNA 3.1 Hygro (+) vector to create γ-RlucII, β-RlucII and µ1-RlucII. Human γ, β1 362 
and µ1 were amplified by PCR minus the stop codon and subcloned in-frame 5’ of GFP10 into 363 
the pcDNA 3.1 (+) vector to create γ-GFP10, β-GFP10 and µ1-GFP10. PSAP-myc 37 and Arf1-HA 38 364 
were previously described. The various mutants were engineered by site-directed mutagenesis 365 
from the previously described constructs. The various mutations introduced in to Arf1 (Figure 366 
S1), β1 (Figure S2A and B) or  γ (Figure S2C) did not alter their expression compared to wild-type 367 
versions of the proteins. 368 
   369 
Cell culture and transient transfections 370 
 Human embryonic kidney 293 cells (HEK293T) were cultured in Dulbecco’s modified 371 
Eagle’s medium (DMEM) containing L-glutamine supplemented with 10 % fetal bovine serum 372 
and 5 % penicillin/streptomycin at 37 oC in a humidified chamber at 95% air and 5% CO2. The 373 
cells were seeded at a density of 2 X 105/well for 12 well plates, 5 X 105/well for 6 well plates or 374 
3 X 106 for 10 cm dishes, 24 hours prior to transfection. 1 µg/well for 12 well plates, 2 µg/well 375 
for 6 well plates or 8 µg for 10 cm dishes of total DNA were used for transient transfection using 376 
linear 25 kDa polyethyleneimine (3 µg PEI/µg DNA).  377 
 378 
BRET titration experiments 379 
 The various vectors for proteins fused to RlucII were co-transfected in HEK293T cells 380 
seeded in 12-well plates at a low and constant quantity (6 ng for Ar1-RlucII constructs, 40 ng for 381 
β1-RlucII and 70 ng for γ-RlucII) with increasing quantities of the vectors for the different 382 
proteins fused to GFP10 (from 10 ng up to 600 ng). Approximately 48 hours later, the cells were 383 
washed, detached in PBS and transferred to white opaque 96-well plates (Greiner) at a density 384 
of   ̴ 100 000 cells. Total fluorescence was first measured with the infinite M1000 Pro plate 385 
reader from Tecan Group Ltd. (Mannedorf, Switzerland) with the excitation and emission set at 386 
400 nm and 510 nm respectively. The BRET2 substrate coelenterazine 400a was then added to 387 
all wells (5 µM final concentration) and the BRET2 signal was measured 3 min later on the 388 
infinite M1000 Pro. The BRET2 signal was calculated as a ratio of the light emitted at 525 ± 15 389 
nm over the light emitted at 410 ± 40 nm. The BRETnet signal was calculated as the difference 390 
between the BRET2 signal in cells expressing both GFP10 and RlucII constructs and the BRET2 391 
signal from cells where only the RlucII fused construct was expressed. BRET titration curves were 392 
generated by expressing comparable levels of wild-type and mutant versions of the various 393 
RlucII (Figure S1) and GFP10 constructs (Figure S2). To ensure that increasing plasmid levels 394 
resulted in an increased expression of the fluorescence signal per cell, and not the increase in 395 
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the number of cells expressing a similar level of fluorescence, we transfected HEK293T cells in 6 396 
well plates with various concentrations of β1-GFP10 (50, 100, 250 and 1000 ng), and determined 397 
the average fluorescence intensity per cell using immunofluorescence microscopy and image 398 
analysis (Figure S7).  399 
 400 
BRET measurements for Brefeldin A treatment 401 
Appropriate quantities of γ-RlucII(70 ng)/µ1-GFP10 (150-200 ng) or β1-RlucII 402 
(40ng)/β1GFP10 (300 ng) were cotransfected in HEK293T cells to obtain a BRETmax for each pair 403 
of proteins. 24 hours after transfection, the cells were detached in DMEM and transferred to 404 
sterile white opaque 96-well plates. 24 hours later, the cells were washed with DMEM without 405 
phenol red and treated with Brefeldin A (10 µM) or vehicle in DMEM without phenol red for 15 406 
min at 37 oC. The total fluorescence and BRET2 signals were measured as described above. 407 
 408 
BRET rescue experiments 409 
 Various quantities of plasmid coding for γ-RlucII (70 to 100 ng) and µ1-GFP10 (75 to 200 410 
ng) were cotransfected in HEK293T WT or Arf1-KO cells with or without a low quantity (100 ɳg) 411 
of a plasmid coding for Arf1-HA or Arf1W172D-HA. Approximately 48 hours after transfection, 412 
cells were washed and detached in PBS then seeded at a density of approximately 100 000 413 
cells/well in white opaque 96-well plates. The total fluorescence and BRET2 were measured as 414 
described above. Conditions of similar luminescence and fluorescence levels were used for 415 
analysis. 416 
 417 
Membrane isolation assay 418 
 This assay was previously described 39. Briefly, approximately 48 hours after 419 
transfection, HEK293T cells were washed with PBS, detached with 5 mM EDTA in PBS and 420 
following centrifugation, the pellet was snap frozen with liquid nitrogen. The samples were then 421 
resuspended in buffer 1 (0.1 M Mes-NaOH pH 6.5, 1 mM MgAc, 0.5 mM EGTA, 200 µM sodium 422 
orthovanadate, 0.2 M sucrose) and centrifuged at 10 000 g for 5 min at 4 oC. The supernatants 423 
(cytosolic fraction) were collected and the pellets (membrane fraction) were resuspended in an 424 
equal volume of buffer 1.  40 µl of each fraction were transferred to a white 96 well plate 425 
(Greiner) and coelenterazine h was added to a 5 µM final concentration. Total luminescence was 426 
measured in the Infinite M1000 Pro plate reader (Tecan, Morrisville, NC). 427 
 428 
Western blotting 429 
 Approximately 48 hours after transfection with the indicated plasmids, HEK293T cells 430 
seeded in 6 or 12 well plates were washed with PBS, detached with 5 mM EDTA in PBS and lysed 431 
in TNE buffer (150 mM NaCl, 10 mM Tris-HCl pH 7.5, 5 mM EDTA, 0.5% Triton X-100, 0.5%) 432 
containing protease inhibitors for 1 hour at 4 °C under gentle agitation. Lysates were clarified by 433 
centrifugation at 13 000 rpm for 15 minutes at 4 oC and 4X SDS-PAGE loading buffer was added 434 
to the supernatants to a 1X final concentration (50 mM Tris-HCL pH 6.8, 2 % SDS, 01 % 435 
bromophenol blue, 10 % glycerol, 1.25 % β-mercapthoethanol). Proteins were then resolved on 436 
SDS-PAGE, transferred to nitrocellulose membranes and detected by immunoblotting using the 437 
indicated antibody. 438 
 439 
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Secretion assay 440 
 6 well plates seeded with WT or KO HEK293T cells were transfected with PSAP-myc and 441 
the indicated plasmids. Approximately 48 hours after transfection, cells were washed once with 442 
PBS and incubated with 1 ml of Opti-Mem for 5 hours at 37 oC in a humidified chamber at 95% 443 
air and 5% CO2. The Opti-Mem containing secreted proteins was collected and trichloroacetic 444 
acid was added to a final concentration of 20 % to precipitate proteins. After a 1 hour incubation 445 
at 4 oC, samples were centrifuged for 5 min at 21 000 g at 4 oC. The pellets were washed with 446 
200 µl of cold acetone, centrifuged and washed again with acetone. After evaporating the 447 
acetone at 95 oC for 1 min, the pellets were resuspended in 2X SDS-PAGE loading buffer. In 448 
parallel, total cell lysates were prepared as described before and proteins were then resolved on 449 
SDS-PAGE, transferred to nitrocellulose membranes and detected by immunoblotting using the 450 
indicated antibody. 451 
 452 
Co-immunoprecipitation 453 
 HEK293T cells seeded in 10 cm dishes were transfected with the indicated plasmid and 454 
48 hours later, the cells were washed with PBS, detached with PBS/EDTA and lysed in TNE buffer 455 
for 2 hours at 4 oC under gentle agitation. The lysates were clarified by centrifugation at 13 000 456 
rpm for 25 min at 4 oC and then pre-cleared with protein-G sepharose for 1 hour at 4 oC. Protein-457 
G sepharose and the indicated antibodies were added to the supernatants followed by an 458 
overnight incubation at 4 oC. The precipitates were washed five times in TNE buffer and the 459 
proteins eluted 1 h at room temperature in 50 µl of SDS-PAGE loading buffer (125 mMTris-HCl, 460 
pH 6.5, 4 % SDS, 2 M urea, 5 % glycerol, 0.1 % bromophenol blue). Proteins were then resolved 461 
on SDS-PAGE, transferred to nitrocellulose membranes and detected by immunoblotting using 462 
the indicated antibody. 463 
 464 
Immunofluorescence microscopy 465 
 HEK293T cells seeded on 12mm coverslips were transfected with the indicated plasmid 466 
and 36 later, the cells were washed with PBS and fixed in 4% paraformaldehyde for 15 minutes. 467 
The cells were then washed with PBS, and incubated with 0.1% saponin for 10 minutes. The cells 468 
were subsequently immunostained with primary antibody for 1 hours at RT, washed in PBS and 469 
the incubated with the appropriate secondary antibody. Cells were then incubated with DAPI for 470 
1 minute, prior to being mounted onto glass slides with Fluoromount G and sealed with nail 471 
polish. Images were acquired on a Zeiss inverted microscope. Image analysis to quantify 472 
fluorescence intensity was performed using Zen Pro software (Carl Zeiss Inc, Mississauga, ON). 473 
 474 
Data and statistical analysis 475 
 All graphs were generated and analyzed using GraphPad Prism (GraphPad Software Inc.) 476 
and the BRET50 and BRETmax were extrapolated from non-linear regression fits using the one-site 477 
saturation binding fitting. All the titration curves shown are representative of at least three 478 
independent experiments. Statistical analysis were done using student’s t-test or one-way 479 
analysis of variance (ANOVA) followed by Tukey’s or Dunnet’s post-hoc tests as appropriate (see 480 
figure legends). 481 
 482 
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Figure legends 613 
Figure 1. Functionality of the RlucII and GFP10 constructs used for BRET. (A) Arf1 recruitment to 614 
membranes was measured in HEK293T cells transfected with either Arf1-RlucII or Arf1Q71L-RlucII.  615 
Cytosol (grey bars) and membrane compartments (black bars) were separated by cell 616 
fractionation and the luminescence was measured in each fraction. Results are expressed as a % 617 
of total luminescence. (B) Co-immunoprecipitation of β1-GFP10 with endogenous γ was 618 
detected in HEK293T cells transfected with β1-GFP10. β1-GFP10 was immunoprecipitated with 619 
an antibody against GFP and endogenous γ was detected by Western blot (Wb) using and anti-γ 620 
antibody. Western blot images were cropped for space considerations. 621 
 622 
Figure 2. Detection of the interaction between Arf1 and the AP-1 subunit β1 in HEK293T cells 623 
using BRET. (A) HEK293T cells were transfected with a fixed concentration of Arf1-RlucII (black 624 
curve), Arf1Q71L-RlucII (red curve), Arf1T48S-RlucII (blue curve) or Arf1T48S,Q71L-RlucII (green curve) 625 
and increasing concentrations of β1-GFP10. Fluorescence and BRET2 were measured in parallel. 626 
15 
BRETnet levels are plotted as a function of the ratio of fluorescence over luminescence 627 
(GFP10/RlucII). Data points are mean ± SEM of triplicates. (B) BRET50 for each Arf1 construct are 628 
shown as mean ± SEM of 4 independent experiments analyzed by ANOVA followed by Tukey’s 629 
post-hoc test. *P ˂ 0.05; ***P ˂ 0.001; ns, not significant.  (C) Arf1Q71L-RlucII was co-transfected 630 
with increasing quantities of full-length β1-GFP10 (black curve) or truncated β11-584-GFP10 (blue 631 
curve) and BRET2 signals were measured. Data points are mean ± SEM of triplicates. (D) BRETmax 632 
and (E) BRET50 are represented as the mean ± SEM of three independent experiments analyzed 633 
by paired student t-test to assess statistical significance. *P ˂ 0.05; ns, not significant.  634 
 635 
Figure 3. Mutations in β1 leads to decreased interaction between Arf1 and AP-1 as detected by 636 
BRET titration experiments in living cells. (A) The effect of mutating the β1 subunit on binding 637 
was tested in HEK293T cells transfected with a low and constant amount of Arf1Q71L-RlucII and 638 
increasing concentrations of β1-GFP10 (black curve), β1I85D,V88D-GFP10 (blue curve) or β1Q59E-639 
GFP10 (red curve). (B) BRET50 for each β1 construct as represented as the mean ± SEM of 4 640 
independent experiments analyzed by ANOVA followed by Tukey’s post-hoc test. ***P ˂ 0.001; 641 
ns, not significant. (C) β1-GFP10 or the indicated mutant were immunoprecipitated using an 642 
anti-GFP antibody and the amount of endogenous γ co-immunoprecipitated was detected by 643 
western blot using an anti-γ antibody. Lysate represents 10% of the input. Western blot images 644 
were cropped for space considerations. 645 
 646 
Figure 4. Reduced interaction between AP-1 and Arf1 mutants detected by BRET. Arf1Q71L-RlucII 647 
or various switch 1 (A) or switch 2 (C) mutated forms of Arf1 were transfected at a low and 648 
constant amount along with increasing quantities of β1-GFP10 into HEK293T cells. The BRET2 649 
signals were measured. BRET50 for each switch 1 (B) or switch 2 (D) mutated forms of Arf11 are 650 
shown as the mean ± SEM of 5 independent experiments analyzed by ANOVA followed by 651 
Dunnett’s post-hoc test. *P ˂ 0.05; **P ˂ 0.01; ***P ˂ 0.001; ns, not significant.  652 
 653 
Figure 5. Effect of mutating the γ subunit on the interaction between AP-1 and Arf1. (A) This 654 
interaction was tested in HEK293T cells transfected with a constant amount of Arf1Q71L-RlucII 655 
and increasing concentrations of γ-GFP10 (black dots), γ L68D,L71E-GFP10 (blue dots) or γL102D-656 
GFP10 (red dots). BRET2 signals were measured. (B) HEK293T cells were co-transfected with 657 
wild-type (WT) γ-GFP10 or the indicated mutants and β1-RLucII. γ-GFP10 was 658 
immunoprecipitated using an anti-GFP antibody and the amount of β1-RlucII co-659 
immunoprecipitated was detected by Western blot (Wb) using an anti-RLuc antibody. Western 660 
blot images were cropped for space considerations. 661 
 662 
Figure 6. The back-side region of Arf1 does not contribute to AP-1 binding in vivo. (A) BRET 663 
titration curves were generated by transfecting HEK293T cells with Arf1Q71L-RlucII (black curve), 664 
Arf1Q71L,W172D-RlucII (blue curve) or Arf1Q71L,A136,137H-RlucII and increasing quantities of β1-GFP10 665 
and BRET signals were measured. (B) BRET50 for each Arf1 construct are shown as the mean ± 666 
SEM of 3 independent experiments analyzed by ANOVA followed by Tukey’s post-hoc test. ns, 667 
not significant. 668 
 669 
16 
Figure 7. The back-side region of Arf1 participates in the allosteric activation of AP-1 in vivo. (A) 670 
HEK293T cells transfected with γ-RlucII/µ1-GFP10 or β1-RlucII/β1-GFP10 were treated with 671 
vehicle (grey bars) or Brefeldin A (BFA, black bars) and BRET signals were measured. Data are 672 
represented as the mean ± SEM of three independent experiments analyzed by paired student t-673 
test to assess statistical significance. ***P ˂ 0.001; ns, not significant.(B) γ-RlucII and µ1-GFP10 674 
were transfected in HEK293T cells with or without Arf1Q71L-HA or Arf1Q71L,W172D-HA and BRET 675 
signals were measured. BRET signals shown are observed at similar levels of 676 
fluorescence/luminescence ratios. Data are shown as the mean ± SEM of six independent 677 
experiments analyzed by one-way ANOVA followed by Tukey’s post-hoc test to assess statistical 678 
significance. **P ˂ 0.01; ***P ˂ 0.001; ns, not significant. (C) The level of expression of Arf1Q71L-679 
HA and Arf1Q71L,W172D-HA were determined by Western blot using an anti-HA antibody.  680 
 681 
Figure 8. Rescue experiments in Arf1-KO cells confirms the allosteric function of Arf1 back-side 682 
(A). A constant amount of γ-RlucII along with increasing quantities of µ1-GFP10 were transfected 683 
in HEK293T (black curve) or Arf-KO (blue curve) cells and BRET signals were measured. Data 684 
points are shown as mean ± SEM of triplicates.  BRET50 (B) and BRETmax (C) are represented as 685 
mean ± SEM of 4 independent experiments analyzed by ANOVA followed by Tukey’s post-hoc 686 
test. **P ˂ 0.01; ns, non significant.(D) HEK293T or Arf1-KO cells were transfected with γ-RlucII, 687 
µ1-GFP10 and Arf1-HA or Arf1W172D-HA and BRET signals were measured. BRET signals shown are 688 
observed at similar level of fluorescence/luminescence ratios. Data is represented as mean ± 689 
SEM of 4 independent experiments and their statistical significance were assessed by ANOVA 690 
followed with Tukey’s post-hoc test. **P ˂ 0.01; ***P ˂ 0.001; ns, non significant.(E) HEK293T or 691 
Arf1-KO cells were transfected with prosaposin-myc (PSAP-myc) with or without Arf1-HA or 692 
Arf1W172D-HA. The amount of PSAP-myc secreted in the media was determined by western blot 693 
using an anti-myc antibody. Western blot images were cropped for space considerations. 694 
 695 
Figure 9. Arf1 increases AP-1 oligomerization in living cells. (A) HEK293T cells were transfected 696 
with β1-RlucII and β1-GFP10 and a membrane isolation assay was performed to separate 697 
cytosolic (C) and membrane fractions (M). BRET2 signals were measured in each fraction. BRET2 698 
signals shown are observed at similar level of fluorescence/luminescence ratios. Data are shown 699 
as the mean ± SEM of three independent experiments analyzed by paired student t-test to 700 
assess statistical significance. ***P ˂ 0.001. (B) The level of expression of Arf1Q71L-HA and 701 
Arf1Q71L,W172D-HA was determined by Western blot using an anti-HA antibody. (C) A low and 702 
constant amount of β1-RlucII and increasing concentrations of β1-GFP10 were co-transfected in 703 
HEK293T cells with or without Arf1Q71L-HA or Arf1Q71L,W172D-HA and BRET2 signals were measured. 704 
(D) BRET50 are displayed as mean ± SEM of 6 independent experiments and their statistical 705 
significance were assessed by ANOVA followed with Tukey’s post-hoc test. **P ˂ 0.01; ***P ˂ 706 
0.001; ns, non significant. (E) A membrane isolation assay was performed on HEK293T cells 707 
transfected with β1-RlucII and Arf1Q71L-HA or Arf1Q71L,W172D-HA. The amount of β1-RlucII in 708 
cytosolic and membrane fractions was determined by measuring the luminescence coming from 709 
RlucII. 710 









